Regeneron: Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results

 

• Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo
• Dupixent is the first and only investigational biologic for COPD that has significantly improved lung function at 12 and 52 weeks, with numerical improvements seen as early as 2 weeks
• Dupixent significantly improved quality of life, with numerical improvements as early as 4 weeks after initiating treatment, and respiratory symptoms
• COPD is the third leading cause of death worldwide, with no new treatment approaches approved in more than a decade; trial enrolled patients with moderate-to-severe disease and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells/µL)

https://www.biospace.com/article/releases/dupixent-dupilumab-late-breaking-phase-3-copd-results-presented-at-ats-and-simultaneously-published-in-the-new-england-journal-of-medicine/